Method of preventing restenosis following coronary angioplasty
Patent 5523292 Issued on June 4, 1996. Estimated Expiration Date: June 4, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/21, Produced by or extracted from animal tissue514/8, Glycoprotein (carbohydrate containing)514/822, ANTICOAGULATION530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/855, PROTEINS FROM ANIMALS OTHER THAN MAMMALS OR BIRDS530/856Snakes; venom
The present invention comprises a method of alleviating restenosis, post-PTCA or other coronary arterial intervention, and more particularly, to the use of ancrod to prevent restenosis in the coronary arteries.
Other References
Canadian Journal of Surgery, vol. 33, No. 3, 1990, Toronto, pp. 207-210 Cole, C. W. et al "Heparin-Associated Thrombocytopenia and Thrombosis:Optimal Therapy with Ancrod", p. 208, col. 3, results
Journal of Nuclear Medicine, vol. 33, No. 5, May 1992, New York, pp. 845-856 Schwartz R. S. et al. "Fibrin Deposition Following Coronary Artery Injury" Quantitation by I-125 Fibrinogen in a Porcine Restenosis Model
"The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms", Robert S. Schwartz et al, JACC vol. 20, No. 5, Nov. 1, 1992:1284-93
"Use of Defibrinating Agents Ancrod and Reptilase in the Treatment of Thromboembolism"; H Kwann; pp. 239-251, 1973
"Therapeutic Defibrination in the Treatment of Thrombotic Disease"; W. R. Bell; pp. 490-493, 1968
"Blood Fibrinolytic Activity during Arvin Therapy"; W. R. Pitney et al; pp. 165-171, 1969
"Prolonged Coagulation Defect (Defibrination Syndrome) in Malayan Viper Bite"; pp. 621-626; 1963
"The Isolation and Properties of the Thrombin-like Activity from Ancistrodon Rhodostoma Venom"; M. P. Esnauf et al; pp. 582-590, 1967
"Direct Effect of Fibrinogen-clotting Enzymes on Plasminogen Activator Secretion from Human Endothelial Cells"; T. Soszka et al; Thrombosis and Haemostasis 54: 164, 1985
"Effects of Ancrod: Normalization of Fibrinolytic Enzyme Abornmalities in Patients with SLE and Lupus Nephritis":; P. Glas-Greenwalt et al; J Lab Clin Med 105: No. 1, 99-107, 1985
"Lupus Nephritis with Thrombosis and Abnormal Fibrinolysis: Effect of Ancrod Therapy"; K. S. Kant et al; J Lab Clin Med 105: No. 1, 77-88, 1985
"The Effect of Arvin on Blood Coagulating Factors"; W. Bell et al; Brit J. Haemat. 15, pp. 589-602, 1968
"The Action of Arvin on Fibrin Stabilizing Factor (factor XIII)"; G. H. Barlow et al; Res Comm Chem Path Pharm 1: 39-42, 1970
"Arvin in Peripheral Arterial Circulatory Disorders. Controlled Multicenter Trials"; G. K. Wolf; Europ. J. Clin Pharmacol 9: 387-392, 1976
"Controlled Defibrination in the Treatment of Peripheral Vascular Disease"; J. A. Dormandy et a;; Angiology 29: 80-88, 1978
"The Effects of Ancrod, the Coagulating Enzyme from the Venom of Malayan Pit Viper (A. rhodostoma) on Prothrombin and Fibrinogen Metabolism and Fibrinopeptide A Release in Man"; W. R. Bell; J Lab Clin Med 91: 592-604, 1978
"In Vivo Effects of Agkistrodon Rhodostoma Venom. Studies with Fibrinogen"; E. Regoeczi et al; I. J. Clin Invest 45: 1202-1212, 1966
"Defibrinogenating Enzymes"; W. R. Bell; Chapter 45 from Colman R, et al (Eds). Hemostasis and Thrombosis. J. B. Lippincott. Phila; pp. 886-900, 1987
"Isotopic Studies of Therapeutic Coagulation with a Coagulating Enzyme"; W. Bell; J. Clin Invest 49: 1872-1879, 1970
"Possible Pathway for Formation of Fibrin Degradation Products During Ancrod Therapy"; C. McKillop et al; Nature (London) 255: 638-639, 1975
"Anticoagulant Therapy with a Purified Fraction of Malayan Pit Viper Venom"; A. A. Sharp et al; Lancet 1: 493-99, 1968
"Deficiency of a Plasma Factor Stimulating Vascular Prostacyclin Generation in Patients with Lupus Nephritis and Glomerular Thrombi and its Correction by Ancrod": In-vivo and in-vitro Observations; K. S. Kant et al; Thromb Res 27: 651-58, 1982
"The Laboratory Investigation of Fibrinolysis". In: Coagulation and Hemostais; G. Lower et al; Thompson J (ed). Churchill-Livingston., Edinburgh 222-260, 1980
"The Place of Thrombolytic and Defibrinating Agents in the Treatment of Venous Thromboembolism": In: Thromboembolism: Advances in Etiology, Prevetnion, and Management.; H. Kwaan et al; Advances in Etiology, Prevetnion, and Management. Nicholaides A (Ed.). MTP Medical Publ. Lancaster, England, 251-267, 1975
"Fibrinolysis in Vivo Predicts a Favorable Outcome in Patients with Glomerular Thrombi During Treatment with Ancrod"; S. Kant et al; The Seoul Journal of Medicine, vol. 29, No. 2: 155-165, Jun. 1988
"Production of the Generalized Shwartzman Reaction in Rabbits by Ancrod (`Arvin`) Infusion and Endotoxin Injection"; C. Krishnamurti et al; Brit. J. Maemat 25: 111-122, 1973
"Precipitation of Ancrod-Induced Soluble Fibrin by Aprotinin and Norepinephrine"; Muller-Berghaus et a;; Thrombosis Research 2: 305-322, 1973
"The Effect of Intraperitoneal Malayan Pit Viper Venom on Adhesion and Peritoneal Healing"; E. C. Ashby et al; Brit U. Surg. 57: 863, 1970
"Acquired Resistance to Treatment with Arvin"; W. Pitney et al; Lancet 1: 79-81, 1969
"In Vivo Behavior of the Coagulant Enzyme from Agkistrodon Rhodostroma Venom: Studies Using I-Arvin"; E. Regoeczi et al; Br J. Maemat 16: 573, 1969
"Effect of a Fibrinolytic Agent (Arvin) on Wound Healing and Collagen Formation"; P. J. L. Holt et al, Heberden Society, p. 335. No date given
"Effects of Arvin in Mice"; Simone Silberman et al; Experimental and Molecular Pathology 14, 67-74, 1971
"Pharmacology and Toxicology of a Defibrinating Substance from Malayan Pit Viper Venom"; A. Ashford et al; Pharmacology Department, Twyford Laboratories Limited, London N.W. 10. The Lancet pp. 486-489 1968
"Experimental Arterial Thromboembolism in Baboons"; Laurence A. Harker et al; The American Society for Clinical Investigation, Inc.; vol. 64, Aug. 1979, pp. 559-569
"Stimulation of Fibrinogen Synthesis by Thrombin in Rabbits with Ancrod-Induced Afibrinogenenmia"; Barbara M. Alving et al; Amer. J. Physiol. Now, vol. 233: 562-567, 1977
"Effects of Ancrod (Arvin) in Mice: Studies of Plasma Fibrinogen and Fibrinolytic Activity", Simone Silberman et al; British Journal of Haematology, 1973, 24, 101
"Fibrinogen-Independent Release of Plasminogen Activator in Ancrod-Treated Rabbits"; C. Krishnamurti et al; Thrombosis and Haemostasis 54: 170 (abstract), 1985
"The Effect of Arvin Upon Cardiac Function"; M. Klein et al; Proceedings of the Society for Experimental Biology and Medicine, vol. 132: 1123-1126, 1969
"Comparison of Ancrod and Heparin as Anticoagulants Following Endarterectomy in the Dog"; T. M. Daniel et al; Ann. Surg. August: 223-228, 1976
"Arvin Treatment for Sickle-Cell Crisis"; The Lancet, pp. 542-543, Sep. 7, 1968
"Streptokinase in Acute Myocardial Infarction"; The New England Journal of Medicine, vol. 301, No. 15, Oct. 11, 1979, pp. 797-802
"Plasminogen Activator Inhibitor: A Physiologic Regulator of Fibrinolysis"; C. Krishmaurti; AFCR Hematology, Clinical Research, vol. 34, No. 2, 1986
"Ancrod Enhances the Thrombolytic Effect of Urokinase and Recombinant Tissue-Type Plasminogen Activator"; Abstracts, JACC, vol. 9, No. 2, Feb. 1987
"Controlled Trail of Ancrod and Heparin in Treatment of Deep-Vein Thrombosis of Lower Limb"; Davies et al; The Lancet, Jan. 15, 1972, pp. 113-115
"Subcutaneous Ancrod in Prevention of Deep Vein Thrombosis After Hip Replacement Surgery"; Belch et al; Thrombosis Research 25; 23-31, 1982
"Treatment of Central Retinal Vein Thrombosis with Ancrod"; Bowell et al; The Lancet, Jan. 24, 1970, pp. 173-174
"Central Retinal Vein Thrombosis", Gent et al; Thrombosis Research 14; 61-66. 1979
"Low-Dosage Ancrod for Prevention of Thrombotic Complications after Surgery for Fractured Neck of Femur", Barrie et al; British Medical Journal, Oct. 19, 1974, pp. 130-133
"Subcutaneous Ancrod after Operation for Fractured Hip--a Dose-Ranging and Feasibility Study"; Lowe et al; Thhrombos. Haemostas., 1978.40, pp. 134-143
"Controlled Trial of Ancrod in Ischemic Stroke"; Hossmann et al; Arch Neurol--vol. 40, Dec. 1983, pp. 803-808
"Defibrinogenation with Arvin in Thrombotic Disorders"; W. R. Bell. 1974
"Clinical Effects of Bites by Malayn Viper"; Reid et al; The Lancet, Mar. 23, 1963, pp. 617-621
"The Proteolytic Action of Arvin on Human Fibrinogen"; Ewart et al; Biochem. J. (1970) 118, 603-609
"Characterization of Peptides Released from Human Fibrinogen by Arvin"; Biochim. Biophys. Acta, 200 (1970) 587-589
"The Mechanism of Action of Arvin and Reptilase"; Kwaan et al; pp. 361-368. No date given no source given
"The Effects of Ancrod Anticoagulation on Renal Function in Sheep"; R. T. Olivet et al; Thrombosis Research, vol. 8: 673-682, 1976
"The Use of Ancrod to Prevent Thromobsis on Prosthetic Heart Valves"; M. P. Singh; Thorax 25: 472-476, 1970
"Characterization ofFibrin Degradation Products in Patients on Ancrod Therapy: Comparison with Fibrinogen Derivatives Produced by Plasmin"; C. Prentice et al; Br J Haemat. 27: 77-87, 1974
Verh Dtsch. Gen Inn Med 79: 1397-1400, 1973; A. Ehrly et al; (Figure reproduced for Canadian product Monograph p. 15) on file at KP
"Treatment of Experimental Venous Thrombosis with Streptokinase and Arvin (ARVIN)"; W. Pitney et al; Brit J Surg 58(6): 442-446, 1971
Karas Clin. Cardiol. 14: 791-801 1991
Hermans Am Heart J. 122(1 Pt 1): 171-187 1991
Pollak et al. "Ancrod Causes Rapid Thrombolysis in Patients w/Acute Stroke" Am J Med Sci 299(5) 319-325 1990
Cercek et al. "Ancrod Enhances The Thrombolytic Effect of Streptokinase & Urokinase" Thromb. Res. 47 417-426 1987
Apprill et al. "Ancrod Decreases The Frequency of Cyclic Flow Variations & Causes Thrombolysis Following Acute Coronary Thrombosis" Am Heart J 113(4) 898-906 1987
Bell "Defibringerating Enzymes" Hemostasis & Thrombosis 886-900 198
June 4, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
